Amanote Research
Register
Sign In
Insights Into the RbMgNH System: An Ordered Mixed Amide/Imide Phase and a Disordered Amide/Hydride Solid Solution
doi 10.1021/acs.inorgchem.7b03232.s001
Full Text
Open PDF
Abstract
Available in
full text
Date
Unknown
Authors
Unknown
Publisher
American Chemical Society (ACS)
Related search
Evaluation of the Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Inadequately Controlled With First-Generation Somatostatin Analogs
Frontiers in Endocrinology
Endocrinology
Metabolism
Diabetes
Trial Design of Phase IIIb, Open-Label, Single Arm Study to Evaluate Efficacy and Safety of Pasireotide LAR in Patients With Inadequately-Controlled Acromegaly Despite Treatment With First-Generation Somatostatin Analogues
Endocrine Abstracts
Postoperative Use of Somatostatin Analogs and Mortality in Patients With Acromegaly.
European Journal of Endocrinology
Medicine
Endocrinology
Metabolism
Diabetes
Efficacy and Safety of Diacerein in Patients With Inadequately Controlled Type 2 Diabetes: A Randomized Controlled Trial
Diabetes Care
Internal Medicine
Endocrinology
Advanced
Metabolism
Specialized Nursing
Diabetes
Interpreting Biochemical Control Response Rates With First-Generation Somatostatin Analogues in Acromegaly
Pituitary
Endocrinology
Metabolism
Diabetes
Added Value of Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Predicting Response to Somatostatin Analogs in Patients With Acromegaly
Turkish Neurosurgery
Surgery
Neurology
Progress in the Formulation and Delivery of Somatostatin Analogs for Acromegaly
Therapeutic Delivery
Pharmaceutical Science
What Is the Efficacy of Switching to Weekly Pegvisomant in Acromegaly Patients Well Controlled on Combination Therapy?
European Journal of Endocrinology
Medicine
Endocrinology
Metabolism
Diabetes
Efficacy of the New Long-Acting Formulation of Lanreotide (Lanreotide Autogel) in Somatostatin Analogue-Naive Patients With Acromegaly
Journal of Endocrinological Investigation
Endocrinology
Metabolism
Diabetes
Combined Treatment for Acromegaly With Long-Acting Somatostatin Analogs and Pegvisomant: Long-Term Safety for Up to 4.5 Years (Median 2.2 Years) of Follow-Up in 86 Patients
European Journal of Endocrinology
Medicine
Endocrinology
Metabolism
Diabetes